Landscape of EGFR mutations in lung adenocarcinoma: a single institute experience with comparison of PANAMutyper testing and targeted next-generation sequencing

BACKGROUND: Activating mutations in the tyrosine kinase domain of epidermal growth factor receptor (EGFR) are predictive biomarkers for response to EGFR–tyrosine kinase inhibitor (TKI) therapy in lung adenocarcinoma (LUAD). Here, we characterized the clinicopathologic features associated with EGFR m...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Jeonghyo, Han, Yeon Bi, Kwon, Hyun Jung, Lee, Song Kook, Kim, Hyojin, Chung, Jin-Haeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Pathologists/The Korean Society for Cytopathology 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9510045/
https://www.ncbi.nlm.nih.gov/pubmed/36128861
http://dx.doi.org/10.4132/jptm.2022.06.11

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9510045/
https://www.ncbi.nlm.nih.gov/pubmed/36128861
http://dx.doi.org/10.4132/jptm.2022.06.11

Ejemplares similares